Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Risperi - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Risperi

Approved

STANDARD

Risperi

LIFESQUARE LABORATORIES INC.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: ecb588e9e6077744
Company: LIFESQUARE LABORATORIES INC.
Type: Standard

Approval Details

Approval Id: ecb588e9e6077744
Drug Approval Philippines Name: Risperi
Product Name: Risperi
Registration Number: DRP-6729-04
Brand Name: Risperi
Generic Name: Risperidone
Dosage Form: Tablet
Dosage Strength: 2 mg
Manufacturer: LIFESQUARE LABORATORIES INC.
Distributor: ALTERNATIVE PLATFORM EXCHANGE INC.
Issuance Date: 24 May 2024
Expiry Date: 20 June 2029
Pharmacologic Category: Antipsychotic
Classification: Prescription Drug (Rx)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

ecb588e9e6077744

Type

Standard

Back to Philippines FDA Approvals